

**Supplemental Table S3. Univariate analysis of significant clinico-pathologic parameters to compare between FIGO IB endocervical adenocarcinoma substages**

<b>Variable</b>	<b>Stage IB1 vs IB2</b>	<b>Stage IB2 vs IB3</b>
Age <50 years, ≥50 years	<b>OR=1.55 (1.01-2.38)</b> <b>p=0.044</b>	OR=1.43 (0.79-2.58) p=0.23
Surgical treatment (hysterectomy vs others)	<b>OR=2.14 (1.11-4.12)</b> <b>p=0.02</b>	OR=2.57 (0.56-11.67) p=0.20
Precursor Lesions (absent vs present)	OR=1.43 (0.90-2.26) p=0.12	<b>OR=2.63 (1.35-5.12)</b> <b>p=0.004</b>
HPV status (independent vs associated)	<b>OR=2.61 (1.24-5.46)</b> <b>p=0.009</b>	<b>OR=3.24 (1.55-6.80)</b> <b>p=0.001</b>
Silva pattern (A vs B/C)	OR=1.57 (0.86-2.86) p=0.13	OR=3.40 (0.76-15.14) p=0.08
Histologic grade (G1vs G2/G3)	<b>OR=1.69 (1.07-2.66)</b> <b>p=0.024</b>	<b>OR=3.05 (1.13-8.17)</b> <b>p=0.021</b>
Lymph-vascular invasion	<b>OR=2.31 (1.52-3.53)</b> <b>p=0.00001</b>	<b>OR=3.40 (1.71-6.75)</b> <b>p=0.00001</b>
Lymph node metastases	OR=1.96 (0.91-4.21) p=0.07	OR=2.20 (0.98-4.93) p=0.05

FIGO, International Federation of Gynecology and Obstetrics